2018
Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis.
Cudahy PGT, Warren JL, Cohen T, Wilson D. Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis. American Journal Of Tropical Medicine And Hygiene 2018, 99: 1336-1341. PMID: 30226135, PMCID: PMC6221241, DOI: 10.4269/ajtmh.18-0322.Peer-Reviewed Original ResearchConceptsC-reactive proteinMulti-drug resistant tuberculosisD-dimerMedian C-reactive proteinSerum C-reactive proteinHigher baseline fibrinogenMDR-TB therapyHIV-positive adultsDrug-resistant tuberculosisHIV-positive participantsHigher CRP concentrationsEarly treatment modificationBaseline fibrinogenTreatment initiationResistant tuberculosisCRP concentrationsTreatment modificationTreatment outcomesTreatment responseHigh riskHigh mortalityNormal levelsOlder ageEarly responseFibrinogen
2010
Development of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis Treatment
Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, Mishustin SP, Strelis AK, Andreev YG, Pasechnikov AD, Barnashov A, Tonkel TP, Cohen T. Development of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis Treatment. American Journal Of Respiratory And Critical Care Medicine 2010, 182: 426-432. PMID: 20413630, PMCID: PMC2921603, DOI: 10.1164/rccm.200911-1768oc.Peer-Reviewed Original ResearchConceptsMDR-TB treatmentXDR-TBDrug-resistant tuberculosisMultidrug-resistant (MDR) TBMDR-TB treatment programmeExtensively Drug-Resistant TuberculosisMultidrug-resistant tuberculosis treatmentCox proportional hazards modelDevelopment of XDRMDR-TB therapyTB treatment servicesAmplification of resistanceProportional hazards modelThreefold increaseMDR-TBCavitary lesionsConsecutive patientsAppropriate therapyClinical outcomesTreatment adherenceTuberculosis treatmentInjectable antibioticsTimely initiationPrescribed drugsRetrospective analysis